Department of Medicine

Department of Medicine

  Division of Hematology/Oncology

[Return To Index page]
photo Lisa H. Butterfield, PhD

Professor of Medicine, Surgery and Immunology

Director, UPCI Immunologic Monitoring and Cellular Products Laboratory


Phone: 412-623-1418

Office: Hillman Cancer Center, Research Pavilion 1.27
5117 Centre Ave
Pittsburgh, PA 15213
Phone: 412-623-1418
Fax: 412-624-0264
Administrative Assistant:
Nancy Barca
Address: Hillman Cancer Center, Research Pavilion
5117 Centre Avenue
Pittsburgh, PA 15213
Phone: 412-624-0280
Fax: 412-624-0264
Education and Training
B.S., Biology, Rensselaer Polytechnic Institute, 1986
Ph.D., Biology, University of California Los Angeles, 1993
Postdoctoral Fellowship, University of California Los Angeles, 1995
Postdoctoral Fellowship, University of California Los Angeles, 1998
Research Interest
The Butterfield laboratory studies the interaction between the immune system and cancer. We are primarily interested in melanoma and hepatocellular cancer. In melanoma, the more immunogenic nature of the tumor and the depth to which it has been studied by many groups has created a level of understanding of the molecular changes in the tumor and the variety of the immunological responses occurring in patients which allows for highly detailed study of these responses as well as design of complex immunotherapy clinical trials to induce more potent anti-tumor responses. In hepatocellular cancer, the lack of spontaneous immunity and paucity of known tumor antigens creates an opportunity for study of new immunotherapy for this difficult disease
For my complete bibliography, Click Here.
Selected Publications:
Santos, PM, Butterfield, LH. Dendritic Cell-Based Cancer Vaccines. Journal of Immunology. 2018; 200(2): 443-449.
Geskin, LJ, Akilov, OE, Kwon, S, Schowalter, M, Watkins, S, Whiteside, TL, Butterfield, LH, Falo, LD, Jr. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome. Cancer Immunology Immunotherapy. 2018; 67(3): 423-434.
Butterfield, LH, Zhao, F, Lee, S, Tarhini, AA, Margolin, KA, White, RI, Atkins, MB, Cohen, GI, Whiteside, TL, Kirkwood, JM, Lawson, DH. Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697). Clinical Cancer Research. 2017; 23(17): 5034-5043.
Butterfield, LH. Cancer Vaccines. British Medical Journal. 2015; 350: h988.
Pardee AD, Yano H, Weinstein AM, Ponce AAK, Ethridge AD, Normolle DP, Vujanovic L, Mizejewski GJ, Watkins SC, Butterfield LH. Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma. Journal of Immunotherapy of Cancer. 2015; 3:32: 10.1186/s40425-015-0077-x.
Lawson, DH, Lee, SJ, Zhao, F, Tarhini, AA, Whiteside, TL, Butterfield, LH, Margolin, K, Ernstoff, MS, Atkins, MB, Cohen, GI, Kirkwood, JM. A Randomized Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF VS Peptide Vaccination VS GM-CSF Plus Peptide Vaccination VS Placebo in Patients with "No Evidence of Disease" after Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E4697). Journal of Clinical Oncology. 2015; 33(34): 4066-76.
Pardee AD, Shi J, Butterfield LH. Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. Journal of Immunology. 2014; 193(11): 5723-32.
Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha Fetoprotein DNA Prime and Adenovirus Boost Immunization of Two Hepatocellular Cancer Patients. Journal of Translational Medicine. 2014; 12: 86.
Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D, Kirkwood JM. Ipilimumab plus sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma: A Randomized Clinical Trial. Journal of the American Medical Association. 2014; 312(17): 1744-53.
Vajunovic L, Ballard W III, Thorne SH, Vujanovic N, Butterfield LH. Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10. Oncoimmunology. 2012; 1(4): 448-457.
Notable Achievements
President, Society for Immunotherapy of Cancer (SITC), 2016-2018
Vice-President SITC, 2014-2016
Secretary/Treasurer, SITC, 2011-2014
Member, iSBTc (now SITC) Board of Directors, 2000-2010
Member, Eastern Coopertive Oncology Group-American College of Radiologic Imaging Network (ECOG-ACRIN) Immunology Core Laboratory Director, 2007-present
ECOG-ACRIN Lab Science Liaison of the Melanoma Committee, 2008-present
Member, NCI Immune Response Modifier Pathway Prioritization Working Group, 2009-2010
Member, NIH Cancer Immunopathology and Immunotherapy (CII) Study Section, 2010-2014
Member, NCI Cancer Steering Committee Immunotherapy Working Group, 2015-present
Henry L. Hillman Foundation Award/Hillman Fellow, 2004-2009